Opportunity Title: FDA Pharmaceutical Analysis Fellowships
Opportunity Reference Code: FDA-CDER-2023-1300

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2023-1300

How to Apply ***Connect with ORISE...on the GO!*** Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 9/29/2023 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**

Two research opportunities are available in the Office of Testing and Research (OTR), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) located in St. Louis, Missouri.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.

The project is to develop and validate LC-MS methods to identify, characterize, and quantify genotoxic impurities in pharmaceutical products, and to use the developed methods to screen a variety of drug products to determine the prevalence of genotoxic impurity contamination and identify potential risk factors.

Under the guidance of the mentor the participants will be trained to develop and validate LC-MS method for pharmaceutical impurity identification, characterization and quantification. The participants will also have opportunities to gain knowledge and experience in pharmaceutical development, application assessment and regulation through internal and external trainings, conferences, and involvement in the processes of solving real-world regulatory issues.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. **The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds.** The

participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the St. Louis, Missouri, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications

The qualified candidate should have received a master's or doctoral degree in one of the relevant fields (e.g. Chemistry, Pharmaceutical Science), or be currently pursuing one of the degrees with completion before September 29, 2023. Degree must have been received within five years of the appointment start date.

Candidates with a doctoral degree in pharmacy (Pharm.D.) will also be considered provided that the candidate demonstrates strong analytical chemistry experience.

Eligibility Requirements

- **Degree:** Master's Degree or Doctoral Degree received within the last 60 months or anticipated to be received by 9/29/2023 12:00:00 AM.
- **Discipline(s):**
  - **Chemistry and Materials Sciences** (9 👁)
  - **Environmental and Marine Sciences** (1 👁)
  - **Life Health and Medical Sciences** (48 👁)

Affirmation

I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)

and

Opportunity Title: FDA Pharmaceutical Analysis Fellowships
Opportunity Reference Code: FDA-CDER-2023-1300

I have read the FDA Ethics Requirements.